Drugs / F14
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03541655 | May 2018 → Jun 2019 | — | Arthritis Innovation Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03541655 ↗ |
| Known as | celecoxib | “single, 3.5 mL dose of F14 (celecoxib) concurrent with standard of care analgesia” NCT03541655 ↗ |